Volume 49, Issue 4 , Pages 333-344, April 2010
Cognitive and Psychiatric Predictors to Psychosis in Velocardiofacial Syndrome: A 3-Year Follow-Up Study
To access this article, please choose from the options below
This article was reviewed under and accepted by Ad Hoc Editor Daniel S. Pine, M.D.
This work was funded by National Institute of Mental Health grants MH64824 and MH65481 to Wendy Kates.
Disclosure: Dr. Faraone, in the past year, has received consulting fees and has been on Advisory Boards for Eli Lilly, Ortho-McNeil, and Shire Development, and has received research support from Eli Lilly, Pfizer, Shire, and the National Institutes of Health. In previous years, Dr. Faraone has received consulting fees or has been on advisory boards, or has been a speaker for the following sources: Shire, McNeil, Janssen, Novartis, Pfizer, and Eli Lilly. In previous years he has received research support from Eli Lilly, Shire, Pfizer, and the National Institutes of Health. Drs. Antshel, Shprintzen, Fremont, and Kates, and Ms. Higgins report no biomedical financial interests or potential conflicts of interest.
PII: S0890-8567(10)00086-9
doi:10.1016/j.jaac.2010.01.010
© 2010 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.
Volume 49, Issue 4 , Pages 333-344, April 2010
